112 related articles for article (PubMed ID: 19289395)
1. HER-2 as a target for breast cancer therapy.
Ignatiadis M; Desmedt C; Sotiriou C; de Azambuja E; Piccart M
Clin Cancer Res; 2009 Mar; 15(6):1848-52. PubMed ID: 19289395
[No Abstract] [Full Text] [Related]
2. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
Kurosumi M
Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
[No Abstract] [Full Text] [Related]
3. HER-2, notch, and breast cancer stem cells: targeting an axis of evil.
Korkaya H; Wicha MS
Clin Cancer Res; 2009 Mar; 15(6):1845-7. PubMed ID: 19276254
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
5. Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer.
Harv Womens Health Watch; 2005 Oct; 13(2):1-3. PubMed ID: 16320417
[No Abstract] [Full Text] [Related]
6. Trastuzumab.
Perez EA; Palmieri FM; Brock SM
Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
[No Abstract] [Full Text] [Related]
7. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
Burstein HJ; Winer EP
J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
[No Abstract] [Full Text] [Related]
8. [Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)].
Penault-Llorca F; Jacquemier J; Le Doussal V; Voigt JJ
Ann Pathol; 1999 Sep; 19(4):280-2. PubMed ID: 10544761
[No Abstract] [Full Text] [Related]
9. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
Mahtani RL; Vogel CL
J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
[No Abstract] [Full Text] [Related]
10. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
11. [Trastuzumab (Herceptin) in the adjuvant treatment of HER-2-positive early breast cancer].
Láng I; Hitre E
Magy Onkol; 2006; 50(4):293-302. PubMed ID: 17216002
[TBL] [Abstract][Full Text] [Related]
12. HER2 Intermediate Breast Cancers.
Jensen KC; Nielsen TO; Gilks CB; West RB
Am J Surg Pathol; 2009 Nov; 33(11):1739; author reply 1739-40. PubMed ID: 19745698
[No Abstract] [Full Text] [Related]
13. Trastuzumab faces trials, clinical and otherwise.
Tuma RS
J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
[No Abstract] [Full Text] [Related]
14. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
15. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
Rowan K
J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
[No Abstract] [Full Text] [Related]
16. Expanded use of Herceptin.
FDA Consum; 2007; 41(2):4-5. PubMed ID: 17590893
[No Abstract] [Full Text] [Related]
17. Trastuzumab in breast cancer.
Banna GL; Santoro A
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
[No Abstract] [Full Text] [Related]
18. Trastuzumab and breast cancer.
Strasser F; Betticher DC; Suter TM
N Engl J Med; 2001 Sep; 345(13):996. PubMed ID: 11575296
[No Abstract] [Full Text] [Related]
19. [Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer].
Luo RC; Li AM; Zhang JY; Liao WJ; Ji CY; Miao JX
Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):52-4. PubMed ID: 15059359
[TBL] [Abstract][Full Text] [Related]
20. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
Yaal-Hahoshen N; Safra T
Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
